Search Results - "Wiggins, Barbara S."

Role of P-glycoprotein in Statin Drug Interactions by Holtzman, Carol W., Wiggins, Barbara S., Spinler, Sarah A.

“…Understanding the mechanisms of drug interactions with 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) has become increasingly important…”
Get full text

Intraosseous Drug Administration in Children and Adults During Cardiopulmonary Resuscitation by Buck, Marcia L, Wiggins, Barbara S, Sesler, Jefferson M

“…Objective: To review and assess the available literature on the use of intraosseous (IO) drug administration during cardiopulmonary resuscitation, addressing…”
Get full text

Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia by Wiggins, Barbara S.

“…Cardiovascular (CV) disease remains the leading cause of death in the United States. In addition to lifestyle modifications, current guidelines primarily focus…”
Get full text

Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week by Wiggins, Barbara S, Dixon, Dave L, Neyens, Ron R, Page, 2nd, Robert L, Gluckman, Ty J

“…Millions of individuals in the United States require long-term treatment with an oral anticoagulant. For decades, vitamin K antagonists were the only oral…”
Get full text

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways by Tomaselli, Gordon F, Mahaffey, Kenneth W, Cuker, Adam, Dobesh, Paul P, Doherty, John U, Eikelboom, John W, Florido, Roberta, Hucker, William, Mehran, Roxana, Messé, Steven R, Pollack, Jr, Charles V, Rodriguez, Fatima, Sarode, Ravindra, Siegal, Deborah, Wiggins, Barbara S

“…Careful attention should be given to comorbidities that could worsen bleeding and subsequent outcome.Because of their dependence on renal function for…”
Get full text

2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee by Tomaselli, Gordon F, Mahaffey, Kenneth W, Cuker, Adam, Dobesh, Paul P, Doherty, John U, Eikelboom, John W, Florido, Roberta, Gluckman, Ty J, Hucker, William J, Mehran, Roxana, Messé, Steven R, Perino, Alexander C, Rodriguez, Fatima, Sarode, Ravindra, Siegal, Deborah M, Wiggins, Barbara S

Get full text

2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents by Barua, Rajat S, Rigotti, Nancy A, Benowitz, Neal L, Cummings, K Michael, Jazayeri, Mohammad-Ali, Morris, Pamela B, Ratchford, Elizabeth V, Sarna, Linda, Stecker, Eric C, Wiggins, Barbara S

“…James L. Januzzi, Jr., MD, FACC Chair, ACC Task Force on Expert Consensus Decision Pathways1 Abstract Tobacco use, especially cigarette smoking, is a major…”
Get full text

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association by Wiggins, Barbara S, Saseen, Joseph J, Page, Robert L, Reed, Brent N, Sneed, Kevin, Kostis, John B, Lanfear, David, Virani, Salim, Morris, Pamela B

Get full text

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants by Tomaselli, Gordon F., Mahaffey, Kenneth W., Cuker, Adam, Dobesh, Paul P., Doherty, John U., Eikelboom, John W., Florido, Roberta, Hucker, William, Mehran, Roxana, Messé, Steven R., Pollack, Charles V., Rodriguez, Fatima, Sarode, Ravindra, Siegal, Deborah, Wiggins, Barbara S.

Get full text

Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care by Wiggins, Barbara S., Backes, James M., Hilleman, Daniel

“…The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, also known as “statins” are considered first‐line pharmacologic therapy for reducing…”
Get full text

Select drug-drug interactions with colchicine and cardiovascular medications: A review by Dixon, Dave L., Patel, Jaideep, Spence, Rowan, Talasaz, Azita H., Abbate, Antonio, Wiggins, Barbara S.

“…Several randomized clinical trials have demonstrated the clinical utility of colchicine in the prevention and management of various cardiovascular conditions,…”
Get full text

Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin by Wiggins, Barbara S., Northup, Amanda, Johnson, Dominic, Senfield, Jeffrey

“…Dabigatran, a direct thrombin inhibitor, is an oral anticoagulant indicated for the prevention of stroke in patients with atrial fibrillation (AF) and for the…”
Get full text

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review by Hilleman, Daniel E., Wiggins, Barbara S., Bottorff, Michael B.

“…Introduction Currently available omega-3 (OM-3) fatty acid products in the US are either nonprescription dietary supplements (e.g., fish oils) or prescription…”
Get full text

2023 Atrial Fibrillation Guideline-at-a-Glance by Wiggins, Barbara S., Bhave, Nicole M., Aggarwal, Niti R., Bates, Katie, Bozkurt, Biykem, Erwin, John P., Kumbhani, Dharam J., Panjrath, Gurusher S., Winter, David E., Coylewright, Megan, Cibotti-Sun, Morgane, Moore, Mykela M.

Get full text

Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing ≥ 120 Kilograms versus 60–120 Kilograms by Wiethorn, Eryne E., Bell, Carolyn Magee, Wiggins, Barbara S.

“…Background Direct oral anticoagulants (DOACs) have become favorable choices for anticoagulation due to their fixed-dose schedule, limited need for monitoring,…”
Get full text

Evolocumab: Considerations for the Management of Hyperlipidemia by Wiggins, Barbara S., Senfield, Jeffrey, Kassahun, Helina, Lira, Armando, Somaratne, Ransi

“…Purpose of Review To review the efficacy, safety, pharmacology, and pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9)…”
Get full text

A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review” by Hilleman, Daniel E., Wiggins, Barbara S., Bottorff, Michael B.

Get full text

UPPING THE ANTE ON HEPARIN DOSING: IS IT TIME FOR A CHANGE IN THE MANAGEMENT OF CARDIOVASCULAR PATIENTS IN THE OBESITY ERA? by Wiggins, Barbara S, Floroff, Catherine, Grimmer, Nicole, Steinberg, Daniel, Powers, Eric

“…With UFH dosing based on actual body weight, the dose recommended often results in under dosing in obese patients. [...]many patients may not achieve…”
Get full text

Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update by Wiggins, Barbara S., Dixon, Dave, Bellone, Jessica, Gasbarro, Nicole, Marrs, Joel C., Tran, Rebecca

“…Although the mortality from cardiovascular disease has declined, it remains the leading cause of morbidity and mortality in the United States. Dyslipidemia is…”
Get full text

Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications by Wiggins, Barbara S., Lamprecht, Donald G., Page, Robert L., Saseen, Joseph J.

“…The discovery of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) has enabled individuals to live longer. As a result, HIV…”
Get full text